Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Thrombosis and Haemostasis|December 1, 1996
Percentage of inadequate phlebograms and observer agreement in thromboprophylactic multicenter trials using standardized methodology and central assessmentP Kälebo, S Ekman, S Lindbratt, et al.
Archives of Pathology & Laboratory Medicine|August 24, 1999
Congenital gastrointestinal pacemaker cell tumorS S Wu, T L Buchmiller, P Close, et al.
Thrombosis and Haemostasis|January 1, 1997
Effect of a 15-minute infusion of DDAVP on the pharmacokinetics and pharmacodynamics of REVASC during a four-hour intravenous infusion in healthy male volunteersD M Amin, T G Mant, S M Walker, et al.
The Journal of Bone and Joint Surgery. American Volume|March 1, 1997
Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacementB I Eriksson, S Ekman, S Lindbratt, et al.
The Journal of Trauma|March 1, 1992
Complications of nonoperative management of blunt hepatic injuriesR P Bynoe, R M Bell, W S Miles, et al.
Acta Chirurgica Belgica|November 1, 1983
[A case of mesenteric venous thrombosis. Review of the literature]P Mendes da Costa, J Sternon, V Creteur, et al.
Journal of Cardiovascular Pharmacology|September 1, 1993
Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteersG A Marbet, M Verstraete, J Kienast, et al.
Journal of the American College of Cardiology|October 1, 1993
Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis GroupM Verstraete, M Nurmohamed, J Kienast, et al.
American Journal of Medical Genetics|November 6, 1995
Duplication and loss of chromosome 21 in two children with Down syndrome and acute leukemiaP K Rogan, P Close, J L Blouin, et al.
Coronary Artery Disease|November 1, 1994
Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group)P Close, J Bichler, R Kerry, et al.
Pageof 7